Instructions to Authors 2014

**General Policy.** ANTIcancer RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIIH Open Access Policy.** The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTIcancer RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTIcancer RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

**Tables.** Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.): 1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php) 2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. 3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address: John G. Delinasios International Institute of Anticancer Research (IIAR) Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS, 1st km Kapandritiou-Kalamou Road P.O. Box 22, GR-19014 Kapandriti, Attiki GREECE Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Effects of Valproic Acid in Combination with S-1 on Advanced Pancreatobiliary Tract Cancers: Clinical Study Phases I/II. S. IWAHASHI, T. UTSUNOMIYA, S. IMURA, Y. MORINE, T. IKEMOTO, Y. ARAKAWA, Y. SAITO, D. ISHIKAWA, M. SHIMADA (Tokushima, Japan) ................................................................. 5187

The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC. O. FIALA, M. PESEK, J. FINEK, L. BENESOVA, M. MINARIK, Z. BORTLICEK, O. TOPOLCAN (Pilsen; Prague; Brno, Czech Republic) ........................................ 5193

Association Between Common Genetic Variants in Pre-MicroRNAs and Prognosis of Advanced Gastric Cancer Treated with Chemotherapy. T. TAHARA, M. OKUBO, T. SHIBATA, T. KAWAMURA, K. SUMI, T. ISHIZUKA, M. NAGASAKA, Y. NAKAGAWA, T. ARISAWA, N. OHMIYA, I. HIRATA (Toyoake; Ishikawa, Japan) ............................................................................................................................ 5199


Evaluation of IGF1 Serum Levels in Malignant Melanoma and Healthy Subjects. R. KUCERA, I. TRESKOVÁ, J. VRZÁLOVÁ, S. SVOBODOVÁ, O. TOPOLCÁN, R. FUCHSOVÁ, M. ROUSAROVÁ, V. TRESKA, T. KYDLICEK (Pilsen, Czech Republic) ............................................................................................................................. 5217

Prognostic Role of Vascular Endothelial Growth Factor and its Receptor-1 in Patients with Esophageal Cancer. E. KILIC, S.E. SCHILD, C. THORNS, A. BAJROVIC, D. RADES (Berlin; Hamburg; Lübeck, Germany; Scottsdale, AZ, USA) ................................................................................................................................. 5221

Errata .................................................................................................................................................. 5227
Sorafenib Efficacy in Thymic Carcinomas Seems Not to Require c-KIT or PDGFR-alpha Mutations. M. PAGANO, N.M. ASENSIO SIERRA, M. PANEBIANCO, G. ROSSI, R. GNONI, G. BISAGNI, C. BONI (Reggio Emilia, Italy) .......................................................... 5105

Plasmablastic Lymphoma of the Breast in an Immunocompetent Patient: Long-lasting Complete Response Induced by Chemotherapy and Autologous Stem Cell Transplantation. A. MATIKAS, G. KANELLIS, C. PAPADIMITRIOU, T. PAPADAKI, A. KOTSAKIS, M.A. DIMOPOULOS, V. GEORGOULIAS (Heraklion; Athens, Greece) .......................................................... 5111

Survival in Advanced Diffuse Large B-Cell Lymphoma in Pre- and Post-rituximab Eras in the United States. B.K. SHAH, A. BISTA, B. SHAFII (Lewiston; Moscow, ID, USA) .......................................................................................................................... 5117

90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment. P. MONDELLO, V. PITINI, C. ARRIGO, E. DERENZINI, M. MIAN (Messina; Bologna; Bolzano/Bozen, Italy; Innsbruck, Austria) .......................................................................................................................... 5121

HPV16-L1-specific Antibody Response Is Associated with Clinical Remission of High-risk HPV-positive Early Dysplastic Lesions. G. MEHLHORN, S.K. HAUTMANN, M.C. KOCH, J.D. STREHL, A. HARTMANN, R. HILFRICH, M.W. BECKMANN, H. GRIESSER (Erlangen; Pirmasens; Cologne, Germany) .......................................................................................................................... 5127

Phase I Study of Efatutazone, an Oral PPARγ Agonist, in Patients with Metastatic Solid Tumors. H. MURAKAMI, A. ONO, T. TAKAHASHI, Y. ONOZAWA, T. TSUSHIMA, K. YAMAZAKI, T. JIKOH, N. BOKU, N. YAMAMOTO (Shizuoka; Tokyo; Kanagawa; Wakayama, Japan) .......................................................................................................................... 5133

8-Isoprostone in Exhaled Breath Condensate of Patients with Nonsmall Cell Lung Cancer: The Effect of Chemotherapy. D. STATHOPOULOS, S. LOUKIDES, K. SYRIGOS (Athens, Greece) .......................................................................................................................... 5143

Elderly Women Above Screening Age Diagnosed with Cervical Cancer Have a Worse Prognosis. L. DARLIN, C. BORGFELDT, E. WIDÉN, P. KANNISTO (Lund, Sweden) .......................................................................................................................... 5147


Fibroma of Tendon Sheath with 11q Rearrangements. J. NISHIO, H. IWASAKI, M. NAGATOMO, M. NAITO (Fukuoka, Japan) .......................................................................................................................... 5159


Optimal Treatment Change Criteria for Advanced Gastric Cancer with Non-measurable Peritoneal Metastasis: Symptom/Tumor Marker-based Versus CT-based. H. HASEGAWA, K. FUJITANI, S. NAKAZURU, M. HIRAO, K. YAMAMOTO, E. MITA, T. TSUJINAKA (Osaka, Japan) .......................................................................................................................... 5169


D-dimer Levels in the Differential Diagnosis Between Lipoma and Well-differentiated Liposarcoma. A. YOSHIYAMA, T. MORII, T. TAJIMA, T. AOYAGI, K. HONYA, K. MOCHIZUKI, K. SATOMI, S. ICHIMURA (Mitaka, Tokyo, Japan) .......................................................................................................................... 5181

Contents continued on the preceding page
Proteomic Identification of Dihydrolipoamide Dehydrogenase as a Target of Autoantibodies in Patients with Endometrial Cancer. K. YONEYAMA, R. SHIBATA, A. IGARASHI, S. KOJIMA, Y. KODANI, K. NAGATA, K. KUROSE, R. KAWASE, T. TAKESHITA, S. HATTORI (Tokyo; Saitama, Japan) ........................................... 5021

Imatinib Escalation or Sunitinib Treatment After First-line Imatinib in Metastatic Gastrointestinal Stromal Tumor Patients. C.-C. HSU, C.-E. WU, J.-S. CHEN, J.-H. TSENG, K.-C. CHIANG, Y.-Y. LIU, C.-Y. TSAI, C.-T. CHENG, T.-W. CHEN, Y.-Y. JAN, T.-S. YEH, Y.-Y. CHEN, C.-N. YEH (Linkou; Keelung; Kaohsiung, Taiwan, ROC) ............................................................................................................. 5029

Irinotecan plus Cisplatin in Patients with Extensive-Disease Poorly Differentiated Neuroendocrine Carcinoma of the Esophagus. H.S. OKUMA, S. IWASA, H. SHOJI, A. TAKASHIMA, N. OKITA, Y. HONMA, K. KATO, T. HAMAGUCHI, Y. YAMADA, Y. SHIMADA (Tokyo; Chiba, Japan) ................................................................. 5037

The Role of Statins for Primary Prevention in Non-elderly Colorectal Cancer Patients. A. SEHDEV, Y.-C.T. SHIH, D. HUO, B. VEKHTER, C. LYTTLE, B. POLITE (Chicago, IL, USA) .......................................................... 5043

Oxidative Stress and Body Composition in Prostate Cancer and Benign Prostatic Hyperplasia Patients. S. CIMINO, V. FAVILLA, G.I. RUSSO, F. GALVANO, G.L. VOLTI, I. BARBAGALLO, S.V. GIOFRE, N. D’ORAZIO, A. DI ROSA, M. MADONIA, G. MORGIA (Catania; Palermo; Messina; Chieti; Sassari, Italy) ................................................................................................................................. 5051

Implementation of a Clinical Quality Control Program in a Mammography Screening Service of Brazil. S.M. SABINO, T.B. SILVA, A.H.U. WATANABE, K. SYRJÁNEN, A.L. CARVALHO, E.C. MAUAD (Barretos, Brazil; Turku, Finland) .................................................................................................................. 5057

Clinicopathological Characteristics and Therapeutic Outcomes of Synchronous Gastric Adenocarcinoma and Gastric Lymphoma. T. NAMIKAWA, E. MUNEKAGE, I. FUKUDOME, H. MAEDA, H. KITAGAWA, K. TOGITANI, M. TAKASAKI, A. YOKOYAMA, M. KOBAYASHI, K. HANAZAKI (Kochi, Japan) ................. 5067


Radiosurgery Alone for 1-3 Newly-diagnosed Brain Metastases from Melanoma: Impact of Dose on Treatment Outcomes. D. AGNESE, L. BELGIOIA, A. BACIGALUPO, M. MARCENARO, S. VECCHIO, S. AGOSTINELLI, S. MORBELLI, R. CORVÔ (Genoa, Italy) .............................................. 5079

HER2-positive Gastric Cancer Showing Marked Thickening of the Gastric Wall on Ultrasonographic and Computed Tomographic Scans. A Chance Phenomenon or a Specific Behaviour of this Cancer Type? Report of Three Cases. R. DI CICILIA, P. MORDENTI, E. ANSELMI, C. PATIES, E. CARELLA, L. CAVANNA (Piacenza, Italy) ............................................................................................................................... 5083


Contents continued on the preceding page
The Multi-tyrosine Kinase Inhibitor TKI258, Alone or in Combination with RAD001, Is Effective for Treatment of Human Leukemia with BCR-ABL Translocation In Vitro. J. EUCKER, C. ZANG, Y. ZHOU, X. LI, P. HABBEL, C. NEUMANN, C. SCHOLZ, H. LIU (Berlin, Germany; Taiyuan, PR China) ............ 4909

HSP27 Knockdown Produces Synergistic Induction of Apoptosis by HSP90 and Kinase Inhibitors in Glioblastoma Multiforme. L. BELKACEM, M.O. HEBB (London, ON, Canada) ........................................ 4915

Matrix metalloproteinase-2 and -14 in p16-Positive and –Negative HNSCC after Exposure To 5-FU and Docetaxel In Vitro. C. ADERHOLD, C. UMBREIT, A. FABER, R. BIRK, J.U. SOMMER, K. HÖRMANN, J.D. SCHULTZ (Mannheim, Germany) ........................................... 4929


Prognostic Markers in Early-stage Colorectal Cancer: Significance of TYMS mRNA Expression. A. KOUMARIANOU, I. TZEVELEKI, D. MEKRAS, A.G. ELEFTHERAKI, M. BOBOS, R. WIRTZ, E. FOUNTZILAS, C. VALANIS, I. XANTHAKIS, K.T. KALOGERAS, G. BASDANIS, G. PENTHEROUDAKIS, V. KOTOULA, G. FOUNTZILAS (Athens; Thessaloniki; Piraeus; Ioannina, Greece; Cologne, Germany) ........................................................................ 4949


Preventive Effects of Probiotic Bacteria Lactobacillus plantarum and Dietary Fiber in Chemically induced Mammary Carcinogenesis. M. KASSAYOVÁ, N. BOBROV, L. STROJNÝ, T. KISKOVÁ, J. MIKEŠ, V. DEMEČKOVÁ, P. ORENDAŠ, B. BOJKOVÁ, M. PĚČ, P. KUBATKA, A. BOMBA (Košice; Martin, Slovak Republic) ........................................................................................................................................... 4969


Clinical Studies

Pharyngeal and Cervical Cancer Incidences Significantly Correlate with Personal UV Doses Among Whites in the United States. D.E. GODAR, R. TANG, S.J. MERRILL (Silver Spring, MD; Milwaukee, WI, USA) ................................................................. 4993

Primary Peritoneal Angiosarcoma: A Case Report. J. LITVAN, M. AGHAZARIAN, E. WILEY, S. GULERIA, A.Z. DUDEK (Chicago, IL, USA; Montevideo, Uruguay) ........................................................................................................................... 5001

Granulocyte-Colony-Stimulating Factor in Elderly Patients Receiving Chemotherapy for Breast and Gynaecological Cancers: Results of a French Survey. C. FALANDRY, I. KRAKOWSKI, H. CURÉ, E. CAROLA, P. SOUBEYRAN, O. GUÉRIN, G. FREYER (Pierre-Bénite; Vandoeuvre-les-Nancy; Reims; Senlis; Bordeaux; Nice, France) ........................................................................................................ 5007

Intracystic Papillary Carcinoma of the Breast: A Diagnostic Challenge with Major Clinical Impact. C.Y. AKLADIOS, M.-N. ROEDLICH, M.-F. BRETZ-GRENIER, S. CROCE, C. MATHELIN (Strasbourg, France) .................................................................................................................. 5017

Contents continued on the preceding page
Cucurbitacin-D-induced CDKI mRNA Up-regulation Causes Proliferation Arrest of a Non-small Cell Lung Carcinoma Cell Line (NSCLC-N6). C. JACQUOT, B. ROUSSEAU, D. CARBONNELLE, I. CHINOU, M. MALLETER, C. TOMASONI, C. ROUSSAKIS (Nantes, France; Athens, Greece) ........................................... 4797

Active Hexose-correlated Compound Down-regulates Sex determining Region Y-box 2 of Pancreatic Cancer Cells. J. NAWATA, Y. KURAMITSU, Y. WANG, T. KITAGAWA, K. TOKUDA, B. BARON, J. AKADA, S. SUENAGA, S. KAINO, S.-I. MAEHARA, Y. MAEHARA, I. SAKaida, K. NAKAMURA (Yamaguchi; Fukuoka; Shunan-shi, Japan) ........................................................................................................ 4807

Prognostic Significance of ZNF217 Expression in Gastric Carcinoma. A. SHIDA, S. FUJIOKA, H. KURIHARA, Y. ISHIBASHI, N. MITSUMORI, N. OMURA, K. YANAGA (Tokyo; Kanagawa, Japan) .......................................................... 4813

Nogo-B Receptor Expression Correlates Negatively with Malignancy Grade and Ki-67 Antigen Expression in Invasive Ductal Breast Carcinoma. B. PULA, M. OLBROMSKI, T. OWCZAREK, A. AMBICKA, W. WITKIEWICZ, M. UGORSKI, J. RYS, M. ZABEL, P. DZIEGIEL, M. PODHORSKA-OKOLOW (Wroclaw; Krakow; Poznan, Poland) ........................................................................................................ 4819


Tunicamycin Induces Paraptosis Potentiated by Inhibition of BRAFV600E in FRO Anaplastic Thyroid Carcinoma Cells. S.H. KIM, H.-Y. SHIN, Y.-S. KIM, J.G. KANG, C.S. KIM, S.-H. IHM, M.G. CHOI, H.J. YOO, S.J. LEE (Chuncheon; Gyeonggi-Do, Republic of Korea) ........................................................................................................... 4857


A Nelarabine-resistant T-Lymphoblastic Leukemia CCRF-CEM Variant Cell Line Is Cross-resistant to the Purine Nucleoside Phosphorylase Inhibitor Forodesine. T. YAMAUCHI, K. UZUI, R. NISHI, T. TASAKI, T. UEDA (Matsuoka, Fukui, Japan) ........................................................................................................ 4885

Decreased miR-206 Expression in BRCA1 Wild-type Triplenegative Breast Cancer Cells After Concomitant Treatment with Gemcitabine and a Poly(ADP-ribose) Polymerase-1 Inhibitor. A. SASAKI, Y. TSUNODA, M. TSUJI, Y. UDAKA, H. OYAMADA, H. TSUCHIYA, K. OGUCHI (Shinagawa, Tokyo; Kamogawa, Chiba, Japan) ........................................................................................................ 4893

TK2I258, a Multi-tyrosine Kinase Inhibitor Is Efficacious Against Human Infant/Childhood Lymphoblastic Leukemia In Vitro. J. EUCKER, C. ZANG, Y. ZHOU, X. LI, P. HABBEL, C.-O. SCHULZ, C. SCHOLZ, H. LIU (Berlin, Germany; Taiyuan, PR China) ........................................................................................................... 4899
Neutrophil Expression of ICAM1, CXCR1, and VEGFR1 in Patients with Breast Cancer Before and After Adjuvant Chemotherapy. C. LOHRI, C.S. HUTZLI SCHALTEGGER, M. VAN DEN BROEK, R.H. WENGER, C. RUEGG, D. FINK, M.K. FEHR, A. KNUTH, M. ZWEIFEL (Buelach; Maennedorf; Zurich; Fribourg; Bern, Switzerland; Doha, Qatar) ........................................................................................................ 4693

Nanotherapy with Hybrid Liposomes for Colorectal Cancer Along with Apoptosis In Vitro and In Vivo. H. ICHIHARA, S. NAKAGAWA, Y. MATSUOKA, K. YOSHIDA, Y. MATSUMOTO, R. UEOKA (Kumamoto, Japan) ...................................................................................................................................... 4701


PAX3 Loads onto Pericentromeric Heterochromatin During S Phase Through PARP1. T.-F. WU, Y.-L. YAO, I.-L. LAI, T.-H. LEE, D.A. UNDERHILL, W.-M. YANG (Taiichung, Taiwan, ROC; Edmonton, AB, Canada) .................................................................................................................. 4717


Liposomes Ameliorate Crizotinib- and Nilotinib-induced Inhibition of the Cardiac IKr Channel and QTc Prolongation. G.M. SHOOP, L. HELSON, A. BOUCHARD, D. SALVAIL, M. MAJEED (Boulder, CO; Quakertown, PA; East Windsor, NJ, USA; Sherbrooke, QC, Canada) .................................................................................................................................................. 4733


Development of a Novel In Vivo Cancer Model Using Cell Sheet Engineering. R. SUZUKI, A. ARUGA, H. KOBAYASHI, M. YAMATO, M. YAMAMOTO (Tokyo, Japan) .......................................................................................................................... 4747

LLW-3-6 and Celecoxib Impacts Growth in Prostate Cancer Cells and Subcellular Localization of COX-2. T. YEROKUN, L.L. WINFIELD (Atlanta, GA, USA) .................................................................................................................................................................................. 4755


Expression of ABCB6 Is Related to Resistance to 5-FU, SN-38 and Vincristine. K. MINAMI, Y. KAMIJO, Y. NISHIZAWA, S. TABATA, F. HORIKUCHI, M. YAMAMOTO, K. KAWAHARA, Y. SHINSATO, T. TACHIWADA, Z.-S. CHEN, K. TSUJIKA, M. NAKAGAWA, N. SEKI, S.-I. AKIYAMA, K. ARIMA, Y. TAKEDA, T. FURUKAWA (Kagoshima; Yamagata; Osaka; Chiba; Fukuoka, Japan; Queens, NY, USA) .......................................................................................................................................................................................... 4767

Erythrocyte Membrane Fatty Acids Profile in Colorectal Cancer Patients: A Preliminary Study. G. COVIELLO, V. TUTINO, M. NOTARNICOLA, M.G. CARUSO (Castellana Grotte, Italy) .................................................................................................................................................................................. 4775

Analysis of the Tumoricidal and Anti-Cachectic Potential of Curcumin. C. OELKRUG, C.M. LANGE, E. WENZEL, S. FRICKE, M. HARTKE, J. SIMASI, A. SCHUBERT (Leipzig, Germany) .......................................................................................................................................................................................... 4781